StoryOther
Eli Lilly's market capitalization passes $1 trillion
Eli Lilly's stock market value passed $1 trillion on November 21, 2025, the first health-care company to reach that level. Growth was driven by demand for tirzepatide drugs Mounjaro (for diabetes) and Zepbound (for weight loss), putting Lilly in exclusive company alongside tech giants but as only the second non-technology company after Berkshire Hathaway.
- Lilly became the first pharmaceutical company to reach $1 trillion valuation.
- Mounjaro and Zepbound are the primary value drivers.
- Novo Nordisk's shares fell as competition intensified in the GLP-1 market.
- Reflects investor confidence in obesity and diabetes drug markets.